Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in Combination With EBRT [0.03%]
放射性药物在前列腺癌中的应用：一般考虑及其与EBRT联合使用的益处
Caner Civan,Nika Guberina,Ulrich Krafft et al.
Caner Civan et al.
The management of prostate cancer has posed challenges for clinicians in determining optimal treatment strategies. Over the years, various radiopharmaceuticals have been utilized for both the diagnosis and treatment of the prostate cancer. ...
Jacob Pozin,Menal Bhandari,Luca Valle et al.
Jacob Pozin et al.
The detection of local radiorecurrence (LRR) of prostate cancer in the prostate or prostate bed after radiation therapy is increasingly common with the advent of advanced imaging modalities such as the PSMA PET/CT. Our aim is to review the ...
Postoperative Radiation Therapy and Controversies Regarding Hormonal Therapy in the Management of Prostate Cancer [0.03%]
前列腺癌治疗中的术后放疗及有关激素治疗的争议问题
Vérane Achard,Alan Dal Pra,Paul Sargos
Vérane Achard
Biochemical recurrence (BCR) after radical prostatectomy (RP) remains a clinical challenge, with significant heterogeneity in outcomes and optimal management strategies. Salvage radiotherapy (sRT) is the standard approach, yet the role and ...
Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic Therapy Approach [0.03%]
寡转移性激素敏感前列腺癌的系统治疗方案辩论
Gunhild von Amsberg,Moritz Kaune,Anja Coym et al.
Gunhild von Amsberg et al.
Oligometastatic prostate cancer (OMPC) represents an intermediate stage between localized and extensive metastatic disease, characterized by a limited number of metastatic lesions. While metastasis-directed therapy (MDT) has gained traction...
Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer [0.03%]
寡转移前列腺癌的转移灶导向治疗辩论会三期
Maneesh Singh,Vedang Murthy,Piet Ost
Maneesh Singh
Oligometastatic prostate cancer (OMPC), characterized by limited metastatic burden (≤5 lesions), encompasses 3 major subtypes: de novo synchronous oligometastatic hormone-sensitive prostate cancer (om-HSPC), metachronous oligorecurrent HSP...
Debate 2: The Case for Focal External Beam Radiation Therapy Boost Over Brachytherapy Boost for Prostate Cancer [0.03%]
Anna M Dornisch,Tyler M Seibert
Anna M Dornisch
Modern trials demonstrate excellent outcomes for men with localized prostate cancer treated with radiation therapy. However, some patients experience recurrences, and more than one-third of recurrences are localized to the prostate. Treatme...
Debate 2: Primary Localized Prostate Cancer: The Case for Whole-Gland Brachytherapy Boost [0.03%]
局部前列腺癌的辩论：全腺体近距离放疗 boost 的理由
Amani A Chowdhury,Peter J Hoskin
Amani A Chowdhury
Whole gland brachytherapy (BT) boost in combination with external beam radiotherapy (EBRT) improves biochemical relapse free survival (bRFS) for intermediate- and high-risk prostate cancer (PCa). Three randomized control studies (RCT) have ...
Debate 1: High-Risk Localized Prostate Cancer: Why Combination Hormone Therapy and Radiotherapy is the Optimal Treatment Strategy for Most Men [0.03%]
高危局限性前列腺癌：为何联合激素治疗和放疗是大多数患者的首选治疗策略？
Michael K Rooney,Zakaria El Kouzi,Ramez Kouzy et al.
Michael K Rooney et al.
Prostate cancer is the most commonly diagnosed malignancy among men in the United States, with high-risk localized disease accounting for approximately 15% of new cases. High-risk cancer portends increased risk of locoregional recurrence an...
Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer [0.03%]
高危前列腺癌适宜患者手术治疗辩论一——根治性前列腺切除术
Vinaik M Sundaresan,Michael S Leapman
Vinaik M Sundaresan
Prostate cancer is a heterogeneous disease with varying degrees of metastatic potential and responsiveness to treatment. Whether surgical removal or radiation therapy combined with androgen deprivation therapy (ADT) is the best initial cour...
Srinivas Chilukuri,Mutlay Sayan,Alan Dal Pra et al.
Srinivas Chilukuri et al.
Elective nodal radiotherapy (ENRT) targets microscopic pelvic lymph node metastases to improve locoregional control in prostate cancer. Recent randomized trials report improved outcomes, particularly in high-risk cohorts, albeit with modest...